This study evaluates the factors that contribute to chronic graft-versus-host disease, which is a complication that can occur after allogeneic hematopoietic cell transplantation.
Documented written informed consent of the participant and/or parent/guardian.
Assent from pediatric participants will be documented per institutional policies and practice.
Patients who have received allogeneic hematopoietic cell transplant (HCT) regardless of donor type, condition regimen, or GVHD prophylaxis.
Age: ≥ 18 years or ≥ 7 years if 30 kg and above
* Women of childbearing potential: Pregnant/nursing
Individuals with impaired decision-making capacity
An employee who is under the direct/ indirect supervision of the PI/ a co-investigator/ the study manager
A direct study team member
Patients who have received allogeneic hematopoietic cell transplant.
Cohort
Other
Non-Interventional Study
Other interventionNon-interventional study
T cell measurements
Defined as percentage of naïve and memory T cells using high dimensional flow cytometry.
B cell measurements
Defined as percentage of naïve B, memory B, and plasma cells using high dimensional flow cytometry.
Macrophage measurements
Defined as percentage of M1, M2, and M0 using high dimensional flow cytometry.
Click on the lead sponsor to view all of their trials.
City of Hope Medical Center
Lead sponsor
National Cancer Institute (NCI)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
